Breakthrough Test Can Prevent Fatal Kidney Failure

GENTOFTE, Denmark, Sept. 21, 2009 (GLOBE NEWSWIRE) -- Acute kidney injury has
long been recognized as a devastating disorder which often arises as a
complication of other serious illnesses. Despite great efforts to understand and
treat this condition the area has seen little or no improvement in over 60
years. Paradoxically, the incidence of this potentially deadly disorder has been
rising during the last decades and is now reaching epidemic proportions. Each
year, more than 13 million patients suffer acute kidney injury of which more
than 30% have a fatal outcome.

With a move that will prove to be a major advance in the diagnosis of this
growing number of affected patients, Denmark based BioPorto Diagnostics have
announced the successful development of a groundbreaking test called NGAL that
can diagnose acute kidney injury. A test like this has been on the wish list of
doctors worldwide for decades.

"The NGAL test has the potential to revolutionize the way kidney injury is
managed," says Dr. Lars Otto Uttenthal, CSO of BioPorto Diagnostics. Existing
methods of determining kidney injury do not provide useful information about the
state of the patient until one to three days after an injury has occurred. In
contrast, the NGAL test will reveal the occurrence of kidney injury within a few
hours. "Doctors now have an opportunity to predict a patient's outcome -- they
can take proactive steps at an early stage that will prevent kidney injury from
turning into the very dangerous state of established kidney failure," concludes
Dr. Uttenthal.

"The icing on the cake is that the NGAL test is designed to be used on apparatus
that already exists in laboratories and hospitals. In this way we have secured
that the test will be affordable and readily available to doctors worldwide,"
says Thea Olesen, CEO of BioPorto.

In a market that is estimated to be worth over a billion dollars, the NGAL test
could grab a considerable share, solidifying BioPorto's position as the leading
player in the NGAL market. The new NGAL test is developed in collaboration with
one of the world's leading manufacturers of diagnostic tests and is currently
being prepared for production.

The test will be presented in October at ASN Renal Week in San Diego -- the
yearly meeting point for kidney specialists from all over the world.

About BioPorto A/S

BioPorto develops and markets antibodies and antibody-based products, including
tests to diagnose human disease, both for the benefit of individual patients and
to promote efficiency in the health sector. The Company's developments include a
patented test (NGAL) to diagnose and monitor acute kidney injury.

BioPorto was founded in 2000 and is listed on the NASDAQ OMX Copenhagen
(Copenhagen:BIOPOR). www.bioporto.com

-0-
CONTACT: BioPorto A/S
Thea Olesen, CEO
+45 45 29 00 00
info@bioporto.com